The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 27, 2022
Filed:
Aug. 27, 2020
Mirati Therapeutics, Inc., San Diego, CA (US);
Array Biopharma Inc., Boulder, CO (US);
Xiaolun Wang, San Diego, CA (US);
Aaron Craig Burns, San Diego, CA (US);
James Gail Christensen, San Diego, CA (US);
John Michael Ketcham, San Diego, CA (US);
John David Lawson, Carlsbad, CA (US);
Matthew Arnold Marx, San Diego, CA (US);
Christopher Ronald Smith, San Diego, CA (US);
Shelley Allen, Boulder, CO (US);
James F. Blake, Longmont, CO (US);
Mark Joseph Chicarelli, Boulder, CO (US);
Joshua Ryan Dahlke, Longmont, CO (US);
Donghua Dai, Superior, CO (US);
Jay Bradford Fell, Longmont, CO (US);
John Peter Fischer, Longmont, CO (US);
Macedonio J. Mejia, Denver, CO (US);
Brad Newhouse, Boulder, CO (US);
Phong Nguyen, Boulder, CO (US);
Jacob Matthew O'Leary, Denver, CO (US);
Spencer Pajk, Boulder, CO (US);
Martha E. Rodriguez, Boulder, CO (US);
Pavel Savechenkov, Boulder, CO (US);
Tony P. Tang, Boulder, CO (US);
Guy P. A. Vigers, Boulder, CO (US);
Qian Zhao, Boulder, CO (US);
Dean Russell Kahn, Boulder, CO (US);
John Gaudino, Boulder, CO (US);
Michael Christopher Hilton, Boulder, CO (US);
MIRATI THERAPEUTICS, INC., San Diego, CA (US);
ARRAY BIOPHARMA INC., Boulder, CO (US);
Abstract
Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.